Loading clinical trials...
Loading clinical trials...
A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan
Conditions
Interventions
Alfacalcidol
Irbesartan
Locations
3
China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Hunan Chenzhou NO.1 People's Hospital
Chenzhou, Hunan, China
Hunan Yiyang Central Hospital
Yiyang, Hunan, China
Start Date
July 28, 2016
Primary Completion Date
July 30, 2018
Completion Date
December 30, 2018
Last Updated
October 10, 2019
Lead Sponsor
The Third Xiangya Hospital of Central South University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions